Why Moderna Shares Are Falling

Moderna Inc MRNA shares are trading lower by 5.52% to $162.79 Friday morning after the company released interim Phase 3 safety and immunogenicity results for its mRNA-1010 influenza candidate, which did not achieve non-inferiority for the Influenza B strains.

See Also: Peter Schiff Says 'Lot Of Inflation Left In The Pipeline,' Warns Of More Price Hikes

What Else?

Moderna says non-inferiority was not met for seroconversion rates and geometric mean titer ratios for the influenza B/Victoria- and B/Yamagata-lineage strains. The company meanwhile says mRNA-1010 showed an acceptable safety and tolerability profile, and is one of five influenza vaccine candidates being evaluated by Moderna.

Stephen Hoge, M.D., Moderna's President, addressed mRNA-1010 and Influenza B in a statement: "While we did not achieve non-inferiority for the Influenza B strains which are more frequent in younger populations, we have already updated the vaccine that we believe could improve immune responses against Influenza B and will seek to quickly confirm those improvements in an upcoming clinical study thanks to the agility of our mRNA platform."

According to data from Benzinga Pro, Moderna Inc has a 52-week high of $217.25 and a 52-week low of $115.03.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Newswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!